Investment Thesis
Tarsus demonstrates exceptional revenue growth (+146.7% YoY) with improving profitability metrics (-3.8% operating margin approaching breakeven). Strong balance sheet with low leverage (0.21x Debt/Equity), solid cash reserves ($102.2M), and improving per-share economics support near-term path to profitability. Primary concern is negative operating cash flow (-$24.7M), indicating commercialization success has not yet translated to cash generation.
Strengths
- Exceptional revenue growth of 146.7% YoY demonstrating strong commercial execution in pharmaceutical market
- Operating margins approaching breakeven (-3.8%) with improving EPS trajectory (+48.2% YoY improvement)
- Fortress balance sheet with low leverage (0.21x Debt/Equity), $349M equity, and 3.74x current ratio providing financial flexibility
- Cash position of $102.2M sufficient for 4+ year runway at current burn rate
Risks
- Negative operating cash flow (-$24.7M) and free cash flow (-$30.5M) indicate company is unprofitable and burning cash despite revenue growth
- Path to profitability dependent on maintaining 146.7% growth trajectory; any slowdown could extend unprofitability
- Biotech sector inherent risks including regulatory approval, clinical data, competitive dynamics, and reimbursement pressures
- Negative interest coverage (-2.9x) reflects current unprofitability; vulnerable to macro headwinds affecting growth
Key Metrics to Watch
- Operating cash flow trajectory and achievement of positive OCF (critical inflection point)
- Gross margin realization and trend as company scales
- Revenue growth sustainability in subsequent quarters (confirm 146% growth not a one-time event)
- Path to operating profitability based on current margin trajectory and operating leverage
Financial Metrics
Revenue
162.1M
Net Income
-7.0M
EPS (Diluted)
$-0.16
Free Cash Flow
-30.5M
Total Assets
581.1M
Cash
102.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3.8%
Net Margin
-4.3%
ROE
-2.0%
ROA
-1.2%
FCF Margin
-18.8%
Balance Sheet & Liquidity
Current Ratio
3.74x
Quick Ratio
3.71x
Debt/Equity
0.21x
Debt/Assets
40.0%
Interest Coverage
-2.88x
Long-term Debt
72.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:36:52.175658 |
Data as of: 2026-03-31 |
Powered by Claude AI